Switching antipsychotic medication to aripiprazole: position paper by a panel of Italian psychiatrists

Bibliography

• Otsuka Pharmaceutical Europe Ltd. Summary of product characteristics. Abilify (aripiprazole) 5 mg tablets. 2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000471/WC500020170.pdf [Cited 14 October 2014]
   Google Scholar
• Croxtall JD. Aripiprazole: a review of its use in the management of schizophrenia in adults. CNS Drugs 2012;26(2):155-83
   PubMed Web of Science ®Google Scholar
• Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002;63(9):763-71
   PubMed Web of Science ®Google Scholar
• Kasper S, Lerman MN, McQuade RD, et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 2003;6(4):325-37
   PubMed Web of Science ®Google Scholar
• Keck PEJr, Calabrese JR, McIntyre RS, et al. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry 2007;68(10):1480-91
   PubMed Web of Science ®Google Scholar
• Keck PEJr, Calabrese JR, McQuade RD, et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry 2006;67(4):626-37
   PubMed Web of Science ®Google Scholar
• Keck PEJr, Marcus R, Tourkodimitris S, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003;160(9):1651-8
   PubMed Web of Science ®Google Scholar
• Keck PE, Orsulak PJ, Cutler AJ, et al. Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study. J Affect Disord 2009;112(1-3):36-49
   PubMed Web of Science ®Google Scholar
• Kerwin R, Millet B, Herman E, et al. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study. Eur Psychiatry 2007;22(7):433-43
   PubMed Web of Science ®Google Scholar
• McQuade RD, Stock E, Marcus R, et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry 2004;65(Suppl 18):47-56
   PubMed Web of Science ®Google Scholar
• Park MH, Han C, Pae CU, et al. Aripiprazole treatment for patients with schizophrenia: from acute treatment to maintenance treatment. Expert Rev Neurother 2011;11(11):1541-52
   PubMed Web of Science ®Google Scholar
• Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003;60(7):681-90
   PubMed Web of Science ®Google Scholar
• Sachs G, Sanchez R, Marcus R, et al. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol 2006;20(4):536-46
   PubMed Web of Science ®Google Scholar
• Vieta E, Bourin M, Sanchez R, et al. Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial. Br J Psychiatry 2005;187:235-42
   PubMed Web of Science ®Google Scholar
• Wolf J, Janssen F, Lublin H, et al. A prospective, multicentre, open-label study of aripiprazole in the management of patients with schizophrenia in psychiatric practice in Europe: broad Effectiveness Trial with Aripiprazole in Europe (EU-BETA). Curr Med Res Opin 2007;23(10):2313-23
   PubMed Web of Science ®Google Scholar
• Young AH, Oren DA, Lowy A, et al. Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study. Br J Psychiatry 2009;194(1):40-8
   PubMed Web of Science ®Google Scholar
• Pigott TA, Carson WH, Saha AR, et al. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 2003;64(9):1048-56
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Buckley PF. Reducing the burden of side effects during long-term antipsychotic therapy: the role of “switching” medications. J Clin Psychiatry 2007;68(Suppl 6):14-23
   Google Scholar
• De Hert M, Hanssens L, van Winkel R, et al. A case series: evaluation of the metabolic safety of aripiprazole. Schizophr Bull 2007;33(3):823-30
   PubMedGoogle Scholar
• Olfson M, Marcus SC, Corey-Lisle P, et al. Hyperlipidemia following treatment with antipsychotic medications. Am J Psychiatry 2006;163(10):1821-5
   Google Scholar
• Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013;382(9896):951-62
   PubMed Web of Science ®Google Scholar
• Anghelescu I, Wolf J. Successful switch to aripiprazole after induction of hyperprolactinemia by ziprasidone: a case report. J Clin Psychiatry 2004;65(9):1286-7
   Google Scholar
• Lee BH, Kim YK, Park SH. Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry 2006;30(4):714-17
   Web of Science ®Google Scholar
• Casey DE, Carson WH, Saha AR, et al. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl) 2003;166(4):391-9
   PubMed Web of Science ®Google Scholar
• Brown ES, Jeffress J, Liggin JD, et al. Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole. J Clin Psychiatry 2005;66(6):756-60
   PubMed Web of Science ®Google Scholar
• Stroup TS, McEvoy JP, Ring KD, et al. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry 2011;168(9):947-56
   PubMed Web of Science ®Google Scholar
• Byerly MJ, Marcus RN, Tran QV, et al. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study. Schizophr Res 2009;107(2-3):218-22
   PubMed Web of Science ®Google Scholar
• Kim CY, Chung S, Lee JN, et al. A 12-week, naturalistic switch study of the efficacy and tolerability of aripiprazole in stable outpatients with schizophrenia or schizoaffective disorder. Int Clin Psychopharmacol 2009;24(4):181-8
   Google Scholar
• Ryckmans V, Kahn JP, Modell S, et al. Switching to aripiprazole in outpatients with schizophrenia experiencing insufficient efficacy and/or safety/tolerability issues with risperidone: a randomized, multicentre, open-label study. Pharmacopsychiatry 2009;42(3):114-21
   Google Scholar
• Kim SW, Shin IS, Kim JM, et al. Effectiveness of switching to aripiprazole from atypical antipsychotics in patients with schizophrenia. Clin Neuropharmacol 2009;32(5):243-9
   Google Scholar
• Bervoets C, Morrens M, Vansteelandt K, et al. Effect of aripiprazole on verbal memory and fluency in schizophrenic patients : results from the ESCAPE study. CNS Drugs 2012;26(11):975-82
   PubMed Web of Science ®Google Scholar
• Kane JM, Sanchez R, Zhao J, et al. Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia. J Med Econ 2013;16(7):917-25
   PubMedGoogle Scholar
• Luebbe G, Kropp S, Harms E, Ziegenbein M. Extensive weight loss in a patient with schizophrenia after switching from olanzapine to aripiprazole. A case report. Pharmacopsychiatry 2006;39(2):76
   Google Scholar
• Rajarethinam R, Dziuba J, Manji S, et al. Use of aripiprazole in tardive dyskinesia: an open label study of six cases. World J Biol Psychiatry 2009;10(4 Pt 2):416-19
   PubMed Web of Science ®Google Scholar
• Osorio RS, Aguera-Ortiz L, Hurtado de Mendoza A, et al. Treatment of tardive dyskinesia with aripiprazole. Neurotox Res 2010;17(4):432-4
   Google Scholar
• Kuloglu M, Ekinci O, Albayrak Y, Caykoylu A. Benefits of switching women schizophrenic patients to aripiprazole: a case study and brief review of the literature. Arch Womens Ment Health 2010;13(5):443-7
   Google Scholar
• Chen CY, Lin TY, Wang CC, Shuai HA. Improvement of serum prolactin and sexual function after switching to aripiprazole from risperidone in schizophrenia: a case series. Psychiatry Clin Neurosci 2011;65(1):95-7
   Google Scholar
• Basterreche N, Zumarraga M, Arrue A, et al. Aripiprazole reverses paliperidone-induced hyperprolactinemia. Actas Esp Psiquiatr 2012;40(5):290-2
   Google Scholar
• Buckley PF, Correll CU. Strategies for dosing and switching antipsychotics for optimal clinical management. J Clin Psychiatry 2008;69(Suppl 1):4-17
   Google Scholar
• Correll CU. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry 2010;25(Suppl 2):S12-21
   PubMed Web of Science ®Google Scholar
• Pae CU, Serretti A, Chiesa A, et al. Immediate versus gradual suspension of previous treatments during switch to aripiprazole: results of a randomized, open label study. Eur Neuropsychopharmacol 2009;19(8):562-70
   PubMed Web of Science ®Google Scholar
• Pae CU, Chiesa A, Mandelli L, et al. Predictors of early worsening after switch to aripiprazole: a randomized, controlled, open-label study. Clin Drug Investig 2010;30(3):187-93
   Google Scholar
• Fagiolini A. Practical guidance for prescribing with aripiprazole in bipolar disorder. Curr Med Res Opin 2008;24(9):2691-702
   PubMed Web of Science ®Google Scholar
• Lambert TJ. Switching antipsychotic therapy: what to expect and clinical strategies for improving therapeutic outcomes. J Clin Psychiatry 2007;68(Suppl 6):10-13
   PubMedGoogle Scholar
• Sullivan G, Bienroth M, Jones M, et al. Practical prescribing with aripiprazole in schizophrenia: consensus recommendations of a UK multidisciplinary panel. Curr Med Res Opin 2007;23(7):1733-44
   PubMed Web of Science ®Google Scholar
• Fagiolini A, Chengappa KN. Weight gain and metabolic issues of medicines used for bipolar disorder. Curr Psychiatry Rep 2007;9(6):521-8
   PubMedGoogle Scholar
• Praharaj SK, Jana AK, Goyal N, Sinha VK. Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis. Br J Clin Pharmacol 2011;71(3):377-82
   PubMed Web of Science ®Google Scholar
• Tchoukhine E, Takala P, Hakko H, et al. Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week open-label extension phase and both phases of a randomized controlled trial. J Clin Psychiatry 2011;72(3):326-30
   PubMed Web of Science ®Google Scholar
• Joffe G, Takala P, Tchoukhine E, et al. Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2008;69(5):706-11
   PubMed Web of Science ®Google Scholar
• Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27(2):596-601
   PubMed Web of Science ®Google Scholar
• De Fazio P, Girardi P, Maina G, et al. Aripiprazole in acute mania and long-term treatment of bipolar disorder: a critical review by an Italian working group. Clin Drug Investig 2010;30(12):827-41
   PubMed Web of Science ®Google Scholar
• Dulcan MK. editor. Dulcan’s textbook of child and adolescent psychiatry. American Psychiatric Pub, Arlington, VA, USA; 2010
   Google Scholar
• Marcus R, Khan A, Rollin L, et al. Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study. Bipolar Disord 2011;13(2):133-44
   PubMed Web of Science ®Google Scholar
• Yatham LN, Fountoulakis KN, Rahman Z, et al. Efficacy of aripiprazole versus placebo as adjuncts to lithium or valproate in relapse prevention of manic or mixed episodes in bipolar I patients stratified by index manic or mixed episode. J Affect Disord 2013;147(1-3):365-72
   Google Scholar
• de Bartolomeis A, Perugi G. Combination of aripiprazole with mood stabilizers for the treatment of bipolar disorder: from acute mania to long-term maintenance. Expert Opin Pharmacother 2012;13(14):2027-36
   PubMed Web of Science ®Google Scholar
• Woo YS, Bahk WM, Chung MY, et al. Aripiprazole plus divalproex for recently manic or mixed patients with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind maintenance trial. Hum Psychopharmacol 2011;26(8):543-53
   PubMed Web of Science ®Google Scholar
• Vieta E, T’Joen C, McQuade RD, et al. Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study. Am J Psychiatry 2008;165(10):1316-25
   PubMed Web of Science ®Google Scholar
• Cassano GB, Fagiolini A, Lattanzi L, et al. Aripiprazole in the treatment of schizophrenia: a consensus report produced by schizophrenia experts in Italy. Clin Drug Investig 2007;27(1):1-13
   Web of Science ®Google Scholar
• De Filippis S, Cuomo I, Lionetto L, et al. Intramuscular aripiprazole in the acute management of psychomotor agitation. Pharmacotherapy 2013;33(6):603-14
   PubMed Web of Science ®Google Scholar
• McEvoy JP, Citrome L, Hernandez D, et al. Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study. J Clin Psychiatry 2013;74(2):170-9
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Citrome L, Alva G, et al. A trial evaluating gradual- or immediate-switch strategies from risperidone, olanzapine, or aripiprazole to iloperidone in patients with schizophrenia. Schizophr Res 2014;153(1-3):160-8
   PubMed Web of Science ®Google Scholar
• Weiden PJ. Switching in the era of atypical antipsychotics: an updated review. Postgrad Med 2006;Spec No:27-44
   PubMedGoogle Scholar